The Cardiovascular Outcomes Between Liraglutide and Dulaglutide Among Different Chronic Kidney Disease Stages in Patients With Type 2 Diabetes
Authors' conclusion
Both liraglutide and dulaglutide are effective GLP-1 RAs in T2DM patients, but their impact on cardiovascular outcomes varies with CKD stage in liraglutide users. In contrast, this trend was not observed with dulaglutide, suggesting a potentially greater cardiovascular benefit of dulaglutide at more advanced CKD stages.
Study context
- Population
- T2D patients using GLP-1 RAs at various chronic kidney disease (CKD) stages, Chang Gung Research Database, 2011–2019after exclusions
- Participants
- 1,572 patients
- Exposure
- Liraglutide vs dulaglutide across CKD stages
- Liraglutiden = 945
- Dulaglutiden = 627reference
- Outcome
- MACE incidence across CKD stages
Main finding
As reported in the abstract
- Liraglutide: Major Adverse Cardiovascular Events (MACE) HR at eGFR 60-89 ml/min/1.73 m²
- HR 1.401 (95% CI 0.663-2.958)
- Liraglutide: MACE HR at eGFR <15 ml/min/1.73 m²
- HR 4.078 (95% CI 1.111-14.971, P = .0079)
- Dulaglutide: trend of MACE with deteriorating kidney function not observed
- P = .1906
Observational data: associations, not effects.
Original publication
The Cardiovascular Outcomes Between Liraglutide and Dulaglutide Among Different Chronic Kidney Disease Stages in Patients With Type 2 Diabetes. Endocr Pract. Published 15 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →